Vogenx Q3 2026 earnings
Clinical-stage biopharma reports net loss of $4.9 million on $0 revenue, bolstered by $84.4 million net proceeds from August 2026 IPO.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $0 | — | — | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $1.78M (+489% YoY)
- One-offs in the quarter Change in fair value of warrant liability: -$3.44M; Change in fair value of convertible promissory notes payable, related party: -$26.8K
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge No reconciliation provided; GAAP net loss is the reported figure.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and cash equivalents | $5.1M | $0.6M | — | +751% |
| Marketable securities | $77.0M | — | — | — |
| Total cash, cash equivalents, and marketable securities | $82.1M | $0.6M | — | +13,517% |
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported; operating expenses driven by R&D ($1.08M) and G&A ($0.70M).
- EPS story Net loss per share widened to -$0.47 from -$0.05, driven by increased shares outstanding (+91%) and operating expenses.
- One-off check Change in fair value of warrant liability: -$3.44M (non-cash, unrealized).
The good
- Total cash, cash equivalents, and marketable securities: $82.1M
- Net proceeds from IPO: $84.4M
The bad
- Net loss: -$4.9M
- Operating expenses: $1.78M (+489% YoY)
The ugly
- none
Open questions
- What is the specific burn rate for the current cash balance?
- What are the specific terms and maturity dates of the convertible promissory notes payable, related party?
- What is the status of the EMERGE study enrollment?
Full release
Vogenx (VOGX) earnings release, November 6, 2026
Vogenx Reports Third Quarter 2026 Financial
Results and Business Highlights
Advances PBH Development Program Following August
2026 Initial Public Offering
Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities
RALEIGH, NC / ACCESS Newswire / November 6, 2026 – Vogenx,
Inc. (Nasdaq: VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced its financial results for the third quarter and provided a corporate update.
“Our third quarter performance marks a pivotal milestone for
Vogenx following our successful public listing in August," said James Green, Chief Executive Officer of Vogenx. “The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.”
Recent Corporate & Clinical Highlights
Clinical Pipeline Update:
In October 2026, the Company initiated
EMERGE (NCT07760961), a randomized, placebo-controlled, double-blind, parallel-group, Phase 2b study evaluating mizagliflozin 5 mg and
10 mg for 28 days in approximately 36 adults with PBH. The EMERGE study will be conducted at multiple centers in the United States, with topline results expected in the second half of 2027. The Company plans to initiate a Phase 2 study of mizagliflozin for gastroparesis in the first half of 2027.
Initial Public Offering:
In August 2026, the Company completed its $93.4 million IPO, pursuant to which the Company issued and sold 7,187,500 shares of its common stock at a public offering price of
$13.00 per share, including 937,500 additional shares of its common stock pursuant to the exercise in full by the underwriter of its option to purchase shares of common stock from the Company at the IPO price. After deducting underwriting discounts, commissions and offering expenses payable by the Company, the Company received net proceeds from the IPO of approximately $84.4 million.
Leadership and Board Updates:
In September 2026, Ken Toombs was appointed as an independent member of the Vogenx board of directors and chair of the audit committee. In October 2026, Rich Gorman joined the Vogenx management team as Chief Commercial Officer concurrently with his resignation as an independent member of the board of directors, effective
October 12, 2026. Mr. Gorman will lead commercial operations, corporate strategy and business development.
Financial Highlights —————————————————————————————— About Vogenx, Inc.
Vogenx, Inc. (Nasdaq: VOGX) is a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases with high unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. For more information, please visit https://vogenx.com.
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | 1,079,000 | 124,813 | 1,473,697 | 430,517 |
| General and administrative | 703,736 | 177,664 | 1,127,576 | 554,818 |
| Total operating expenses | 1,782,736 | 302,477 | 2,601,273 | 985,335 |
| Other (expense) income | ||||
| Change in fair value of warrant liability | -3,436,669 | 16,984 | -3,426,761 | 43,876 |
| Change in fair value of convertible promissory notes payable, related party | -26,777 | -78,177 | ||
| Interest income | 338,579 | 1,086 | 338,726 | 5,636 |
| Total other (expense) income | -3,124,867 | 18,070 | -3,166,212 | 49,512 |
| Net loss | -4,907,603 | -284,407 | -5,767,485 | -935,823 |
| Net loss per common share – basic and diluted | -0.47 | -0.05 | -0.82 | -0.17 |
| Weighted average common shares outstanding – basic and diluted | 10,404,831 | 5,451,873 | 6,995,883 | 5,451,873 |
Balance Sheet
September 30, 2026 — Unaudited
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | 5,126,137 | 601,010 |
| Deferred offering costs | 63,363 | |
| Marketable securities | 76,991,943 | |
| Prepaid expenses and other current assets | 725,193 | 16,797 |
| Total current assets | 82,843,273 | 681,170 |
| Total assets | 82,843,273 | 681,170 |
| Current liabilities | ||
| Accounts payable | 523,570 | 62,964 |
| Accrued expenses | 318,900 | 709,818 |
| Warrant liability | 11,323 | |
| Convertible promissory notes payable, related party | 816,300 | |
| Total current liabilities | 842,470 | 1,600,405 |
| Total liabilities | 842,470 | 1,600,405 |
| Total stockholders’ equity (deficit) | 82,000,803 | -919,235 |
| Total liabilities and stockholders’ equity (deficit) | 82,843,273 | 681,170 |
Cash Flow
From the 10-Q · Nine Months Ended September 30, — (Unaudited)
| Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | -5,767,485 | -935,823 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 4,524 | 7,863 |
| Change in fair value of warrant liability | 3,426,761 | -43,876 |
| Change in fair value of convertible promissory notes payable, related party | 78,177 | |
| Accretion of discount on marketable securities | -228,385 | |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | -482,717 | -704 |
| Accounts payable | 505,842 | -39,785 |
| Accrued expenses | -390,918 | 283,750 |
| Interest paid on convertible promissory notes payable, related party | -61,151 | |
| Net cash used in operating activities | -2,915,352 | -728,575 |
| Cash flows from investing activities | ||
| Purchase of marketable securities | -76,989,237 | |
| Net cash used in investing activities | -76,989,237 | |
| Cash flows from financing activities | ||
| Proceeds from financing, net of underwriting discounts and commissions | 86,896,875 | |
| Payments of offering costs | -2,467,159 | |
| Net cash provided by financing activities | 84,429,716 | |
| Net increase (decrease) in cash and cash equivalents | 4,525,127 | -728,575 |
| Cash and cash equivalents, beginning of period | 601,010 | 962,923 |
| Cash and cash equivalents, end of period | 5,126,137 | 234,348 |
| Supplemental disclosure of non-cash financing activities | ||
| Conversion of preferred stock into common stock (1,887,144 shares) | 377 | |
| Cashless exercise of warrants into common stock (453,183 shares) | 3,438,084 | |
| Conversion of related-party convertible notes into common stock (64,102 shares) | 833,326 | |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the design, conduct, enrollment, timing and results of the EMERGE Phase 2b study, including the expected timing of topline data; the potential of mizagliflozin to treat post-bariatric hypoglycemia and other indications; anticipated clinical development plans and timelines; the anticipated use of proceeds from the Company's initial public offering, and its capital requirements and need for additional financing; and the potential market opportunity for its product candidates. Words such as "anticipate," "believe," "continue," "estimate," "expect,"
"intend," "may," "plan," "potential," "should," "will" and similar expressions are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the initiation, timing, enrollment and results of clinical trials, the possibility that results of earlier studies may not be predictive of later studies, regulatory review, competition, including the possibility that competitors obtain regulatory approval before the Company, reliance on third parties including clinical research organizations and clinical trial sites, the Company's license from Kissei Pharmaceutical Co., Ltd., the Company's need for additional capital, its limited operating history, its dependence on a small number of key personnel, and the material weaknesses identified in its internal control over financial reporting. Additional information on these and other risks is contained in the Company's filings with the Securities and Exchange Commission (SEC), including the Company’s Quarterly Report on Form 10-Q for quarter ended
June 30, 2026 filed with the SEC on September 17, 2026. Forward-looking statements speak only as of the date of this release, and Vogenx undertakes no obligation to update them except as required by law.²
Vogenx, Inc.
Condensed Balance Sheets
Unaudited³
Vogenx, Inc.
Condensed Statements of Operations
(Unaudited)
Contact
Harrison Seidner, PhD and Nilesh Talele, PhD
WaterSeid Partners, Inc. ir@vogenx.com⁴